The estimated Net Worth of Daron Evans is at least $553 Tisíc dollars as of 12 March 2020. Mr Evans owns over 2,500 units of Nephros Inc stock worth over $252,995 and over the last 5 years he sold NEPH stock worth over $0. In addition, he makes $300,177 as Chief Exec. Officer of Specialty Renal Products a Inc at Nephros Inc.
Mr has made over 5 trades of the Nephros Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of NEPH stock worth $16,625 on 12 March 2020.
The largest trade he's ever made was buying 43,172 units of Nephros Inc stock on 14 June 2019 worth over $25,903. On average, Mr trades about 5,686 units every 30 days since 2019. As of 12 March 2020 he still owns at least 134,215 units of Nephros Inc stock.
You can see the complete history of Mr Evans stock trades at the bottom of the page.
Daron G. Evans is the Chief Exec. Officer of Specialty Renal Products, Inc at Nephros Inc.
As the Chief Exec. Officer of Specialty Renal Products a Inc of Nephros Inc, the total compensation of Mr Evans at Nephros Inc is $300,177. There are 1 executives at Nephros Inc getting paid more, with Andrew Astor having the highest compensation of $309,006.
Mr Evans is 47, he's been the Chief Exec. Officer of Specialty Renal Products a Inc of Nephros Inc since . There are 5 older and 1 younger executives at Nephros Inc. The oldest executive at Nephros Inc is Andrew Astor, 64, who is the CEO, CFO, Pres & Director.
Daron's mailing address filed with the SEC is C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE, NJ, 07079.
Over the last 6 years, insiders at Nephros Inc have traded over $0 worth of Nephros Inc stock and bought 188,822 units worth $443,998 . The most active insiders traders include Capital Lp Wexford Gp Llcda..., Robert R. Jr. Banks a Andrew Astor. On average, Nephros Inc executives and independent directors trade stock every 70 days with the average trade being worth of $15,834. The most recent stock trade was executed by Arthur H Amron on 28 May 2024, trading 5,000 units of NEPH stock currently worth $11,200.
nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
Nephros Inc executives and other stock owners filed with the SEC include: